ACADEMIC RESEARCH IN MODERN SCIENCE
International scientific-online conference
59
MARKETING ANALYSIS OF THE MARKET FOR CARDIOTONIC
DRUGS
N.A.Madatova
Alfraganus University
Tashkent, Republic of Uzbekistan
e-mail: n.madatova@afu.uz, tel: (93) 595-28-63
https://doi.org/10.5281/zenodo.15397091
Relevance:
Cardiotonics are a group of medications used to enhance the
function of the heart muscle, improve its contractile ability, and treat heart
failure. This group includes a significant number of drugs containing various
active ingredients and other mechanisms of action[2].
Purpose of the study:
to analyze the assortment of cardiotonic drugs for
the period of 2019-2023 based on content analysis and DRUG AUDIT data to
study their position in the pharmaceutical market[1].
Materials and methods:
the analysis utilized the "State Register of
Medicines, Medical Devices, and Medical Equipment Permitted for Use in
Medical Practice in the Republic of Uzbekistan" for the period of 2019-2023, the
Essential Medicines List of the Republic of Uzbekistan, and DRUG AUDIT data.
Results:
according to the August 31, 2023 Essential Medicines List of the
Republic of Uzbekistan, in the 11th section (cardiovascular), drugs containing
digoxin as the main active ingredient are listed as cardiotonic agents. According
to the 27th edition of the "State Register of Medicines, Medical Devices, and
Medical Equipment Permitted for Use in Medical Practice in the Republic of
Uzbekistan" for 2023, a total of 18 cardiotonic drugs have been registered in
Uzbekistan. Of these drugs, 14 (78%) are produced by local manufacturers, 3
(16.5%) by foreign manufacturers, and 1 (5.5%) by manufacturers from CIS
countries. In 2019-2020, the number of cardiotonic drugs registered by local
manufacturers increased, while the share of cardiotonic drugs produced by CIS
and foreign manufacturers remained almost unchanged.
The market for cardiotonic drugs during 2018-2022 was analyzed based on
DRUG AUDIT data. The analysis showed that the growth of cardiotonic drugs in
the pharmaceutical market of Uzbekistan slightly decreased in 2018-2019, but
after 2020, the market share of cardiotonic drugs increased yearly, and
proportionally, the production of cardiotonic drugs by local manufacturers also
increased.
Conclusions:
Although cardiotonic drugs produced by foreign
manufacturers have demonstrated a diversity in drug forms in the local market,
the share of cardiotonic drugs produced by local pharmaceutical companies is
ACADEMIC RESEARCH IN MODERN SCIENCE
International scientific-online conference
60
increasing yearly. Since 2018, the number of cardiotonic drugs produced by
local manufacturers has increased, and at the same time, the share of drugs
imported from foreign countries and CIS states has also slightly increased.
Furthermore, it is considered appropriate to produce certain dosage forms
(injectable and infusion solutions, capsules) of cardiotonic drugs available in the
local market and those imported from abroad. Therefore, it is highly relevant to
introduce new pharmacological groups and new dosage forms of cardiotonic
drugs into production by local pharmaceutical companies.
References:
1.
Sarvarova, D. M., Madatova, N. A., Yunuskhodzhaeva, N. A., Iminova, I. M.
Study Of The Assortment Of Antioxidant And Hemostatic Medicines Registered
In The Republic of Uzbekistan. Journal of Pharmaceutical Negative Results,
2023, pp. 1028-1033.
2.
Мадатова Н. Получение лекарственной формы на основе
биологически активных веществ растения пустырник //Каталог
авторефератов. – 2008. – Т. 1. – №. 1. – С. 1-22.
3.
Muxutdinovna
R.
N.,
Abdugaffarovna
M.
N.
O’ZBEKISTON
RESPUBLIKASIDA QAYD ETILGAN BIOLOGIK FAOL QO’SHIMCHALAR
ASSORTIMENT TAHLILI //Eurasian Journal of Medical and Natural Sciences. –
2024. – Т. 4. – №. 1-2. – С. 191-197
